BSW researcher co-authors paper in JAMA Oncology examining Hypofractionated Image-Guided Radiotherapy (IGRT) for non-small cell lung cancer patients

Concurrent radiation therapy and chemotherapy, known as chemoradiation, is a common treatment for locally advanced cancers. Adding concurrent chemotherapy can improve the effectiveness of radiation therapy but can also enhance the appearance of toxic side effects. This means that some cancer patients, especially those with comorbidities or poor health status, are ineligible for concurrent chemoradiation. Researchers at Baylor Scott & White Research Institute (BSWRI) are contributing to critical clinical trials to improve the effectiveness of radiation therapy for cancer patients, including those who are not eligible for concurrent chemoradiation.

Read more

How do we improve patient outcomes with translational research? By educating our future.

From Bench (to Post-graduate Practitioners) to Bedside

Translational research brings new findings from bench to bedside to expedite improvement in patient outcomes. Baylor Scott & White Research Institute (BSWRI) also brings these findings to lecture halls and conferences to ensure postgraduates are well-informed of the latest findings and “best clinical practices” in their disease specialty.

Read more

Research excellence enhanced through Nursing Institute integration

In July 2021, Baylor Scott & White Health (BSWH) launched the Nursing Institute, a system-wide endeavor to elevate the nursing profession by strengthening research, continuing education, and professional excellence. In partnership with Baylor Scott & White Research Institute (BSWRI), the Nursing Institute is driving critical research to improve the practice of nursing and overall administering of care in the hospital environment.

Read more

Lung transplant recipient populations evolve with advances in medical therapies

Cystic fibrosis (CF) and pulmonary hypertension (PH) were once common categories for referral to lung transplant. However, advances in medical therapies have allowed many patients with these diseases to avoid transplant. Today, at most transplant centers throughout the world, lung transplants are being performed on increasingly older patients, primarily with interstitial lung disease (ILD) followed by chronic obstructive pulmonary disease (COPD).  Unlike CF and PH, few treatments with the ability to extend survival currently exist for ILD, specifically idiopathic pulmonary fibrosis (IPF), and COPD. When these patients continue to decline despite maximized medical therapy, surgical options may be indicated.

Read more

Pulmonary hypertension requires early diagnosis and aggressive treatment

The understanding of pulmonary hypertension (PH) continues to evolve. The threshold to diagnose PH was lowered to mPAP ≥ 20 mmHg in the 6th World Symposium on PH in 2018. The therapeutic approach has also changed over time, favoring aggressive use of multiple pulmonary vasodilators in combination upfront and escalation of therapy based frequent assessment of disease progression. The changes to diagnostic criteria and management underscore the need to identify the disease early and to treat it aggressively.  

Read more